Novo Nordisk (NVO) has rallied 38% in the year-to-date period compared with the industry’s 23.3% growth, as seen in the chart below. The stock has also outperformed the sector and the S&P 500. NVO is currently trading near the 52-week high. Novo Nordisk Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchNovo Nordisk, a leader in the worldwide diabetes and obesity care market, has been witnessing stellar performance of its GLP-1 agonist, semaglutide, which is approved as an Ozempic ...